HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

@article{Reynolds2012HER2targetedLD,
  title={HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.},
  author={Joseph G. Reynolds and Elena Geretti and Bart S. Hendriks and Helen Y Lee and Shannon Curtis Leonard and Stephan G. Klinz and Charles O. Noble and Petra B. L{\"u}cker and Peter W. Zandstra and Daryl C. Drummond and Kenneth J. Olivier and Ulrik B. Nielsen and Clet Niyikiza and Samuel V Agresta and Thomas J. Wickham},
  journal={Toxicology and applied pharmacology},
  year={2012},
  volume={262 1},
  pages={1-10}
}
Anthracycline-based regimens are a mainstay of early breast cancer therapy, however their use is limited by cardiac toxicity. The potential for cardiotoxicity is a major consideration in the design and development of combinatorial therapies incorporating anthracyclines and agents that target the HER2-mediated signaling pathway, such as trastuzumab. In this regard, HER2-targeted liposomal doxorubicin was developed to provide clinical benefit by both reducing the cardiotoxicity observed with… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…